查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1949478

肽類藥物市場－全球產業規模、佔有率、趨勢、機會及預測（按應用、類型、製造商、給藥途徑、合成技術、地區和競爭格局分類，2021-2031年）

Peptide Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Type, By Type of Manufacturers, By Route of Administration, By Synthesis Technology, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球胜肽類藥物市場預計將以強勁的速度成長，預計到 2031 年將達到 967.3 億美元，而 2025 年為 569 億美元，複合年成長率為 9.25%。

這些療法被定義為由短氨基酸鏈組成的選擇性訊號分子，因其能夠高效、低毒性地調節特定的生理功能而備受重視。市場擴張主要受慢性代謝性疾病（尤其是糖尿病和肥胖症）日益普遍的推動，這導致對標靶受體促效劑的需求激增。此外，合成製造技術的進步降低了生產門檻，從而擴大了商業性應用範圍。例如，美國化學學會 (ACS) 報告稱，美國食品藥物管理局 (FDA) 在 2023 年核准了9 種胜肽和寡核苷酸類療法，佔當年新藥核准總數的 16%。

市場概覽
預測期 2027-2031
市場規模：2025年 569億美元
市場規模：2031年 967.3億美元
複合年成長率：2026-2031年 9.25%
成長最快的細分市場 代謝性疾病
最大的市場 北美洲

儘管前景樂觀，但肽類藥物產業在藥物傳遞和穩定性方面仍面臨諸多挑戰。肽類藥物的口服生物有效性通常較低，且容易受到酵素分解，因此往往需要頻繁地進行侵入性注射。這種腸外給藥的需求增加了患者依從性，並限制了胜肽類治療方法在慢性病治療中的廣泛應用。因此，如何克服這些藥物動力學限制仍然是該領域面臨的一項重大挑戰，因為該領域正致力於提高長期治療方法的便利性和療效。

市場促進因素

全球代謝性疾病和慢性疾病（尤其是第2型糖尿病和肥胖症）發生率的不斷上升，是推動市場擴張的主要因素。日益加重的疾病負擔使得臨床上更加關注Glucagon-Like Peptide-1(GLP-1) 受體促效劑，這類藥物以其調節食慾和促進胰島素分泌的作用而聞名。因此，大型製藥公司在代謝肽領域實現了顯著的收入成長，這也促使他們擴大生產規模。例如，諾和諾德公司2023年的年度報告預測，截至2024年2月，其肥胖症治療部門的銷售額（經外匯後）將成長154%，達到416億丹麥克朗，這證實了這些療法在文明病管理中的重要作用，以及它們憑藉生物目標分子所取得的商業性成功。

第二個促進因素是生物製藥研發的積極擴張以及旨在獲取創新肽類資產的策略性併購。大型製藥公司正積極收購專業生物技術公司，以獲得下一代促效劑和三重促效劑，這項策略可以降低早期風險並加速產品上市。值得注意的是，2023年12月，羅氏同意以27億美元的預付款收購胜肽類藥物開發商Carmot Therapeutics，顯示該產業正致力於拓展傳統胰島素以外的產品線。為了支持這一成長，製造商也在基礎設施方面投入大量資金。 2023年11月，禮來公司宣布投資25億美元在德國新建一座生產設施，以增強供給能力，特別是注射用胜肽類藥物的供應能力。

市場挑戰

全球肽類藥物市場面臨的主要障礙是肽分子固有的不穩定性及其導致的藥物遞送難題。肽類藥物易受胃腸道和循環系統中酵素的快速分解，導致口服生物生物有效性有限且半衰期短。因此，通常需要皮下或靜脈注射等侵入性給藥方式，以確保藥物能有效到達標靶。這種對頻繁注射的依賴嚴重影響了患者的依從性，尤其對於需要長期治療的慢性疾病而言，從而限制了目標患者群體，並阻礙了整體市場滲透。

此外，開發穩定有效的遞送系統所面臨的複雜性也減緩了新產品通過法規核准流程的進程。這些分子製劑的研發挑戰也反映在核准統計數據中。根據監管事務專業人員協會（RAPS）統計，2024年僅有兩種新型胜肽類療法將獲得FDA核准，僅佔當年核准的50種新分子實體的4%。與傳統小分子化合物相比，如此低的核准率凸顯了研發人員在解決穩定性問題方面持續面臨的困難，並直接限制了成功進入商業市場的新型治療方法的數量。

市場趨勢

將人工智慧應用於胜肽類藥物研發正在改變研發格局，有效解決了最佳化膜滲透性和代謝穩定性等長期存在的難題。先進的運算平台能夠快速篩檢龐大的虛擬化合物庫，在物理合成之前即可辨識出具有優異結合親和性和藥物動力學特性的候選化合物。這項技術進步使研發人員能夠縮短藥物研發週期，並降低早期開發階段常見的高失敗率。例如，Bioduro 於 2025 年 8 月宣布與 Atombeat 建立策略合作夥伴關係，共同部署一個人工智慧驅動的平台，該平台能夠評估超過一兆種潛在的胜肽類化合物，從而加速篩選出有效的治療候選藥物。

同時，新一代胜肽-藥物偶聯物（PDCs）的出現標誌著標靶腫瘤治療領域的重大進步。我們正從簡單的受體促效劑轉向複雜的藥物傳遞系統，這些系統能夠將細胞毒性物質和放射性物質直接輸送到癌細胞。與抗體藥物複合體相比，PDCs具有組織穿透深度深、全身清除速度快等優勢，有助於在維持對固態腫瘤療效的同時，最大限度地減少脫靶毒性。放射性配體療法和創新連結子技術的臨床研究數量顯著增加，也印證了這一趨勢。根據藥明康德2025年6月發布的報告，2024年將啟動超過30項放射性配體-藥物偶聯物的臨床試驗，與前五年相比增加了三倍。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球胜肽類治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依應用領域（癌症、代謝性疾病、心血管疾病、呼吸系統疾病、消化系統疾病、感染疾病、疼痛、皮膚病、神經系統疾病、腎臟疾病、其他疾病）
    • 按類型（學名藥、藥物研發）
    • 依生產方式（自主生產、外包）
    • 依給藥途徑（腸外、口服、肺部、黏膜、其他）
    • 透過合成技術（固相胜肽合成（SPPS）、液相胜肽合成（LPPS）、混合技術）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美胜肽類藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲胜肽類藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區胜肽類藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲胜肽類藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲胜肽類藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球胜肽類藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Eli Lilly and Co.
  • Pfizer Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Co Ltd.
  • AstraZeneca Pharmaceuticals LP
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • F Hoffmann-La Roche AG
  • Novartis AG
  • Novo Nordisk A/S

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24050

The Global Peptide Therapeutics Market is projected to experience robust growth, advancing from a valuation of USD 56.90 Billion in 2025 to USD 96.73 Billion by 2031, reflecting a compound annual growth rate of 9.25%. These therapeutics, defined as selective signaling molecules comprised of short amino acid chains, are valued for their ability to regulate specific physiological functions with high potency and minimal toxicity. The market's expansion is largely fueled by the increasing prevalence of chronic metabolic disorders, particularly diabetes and obesity, which has surged the demand for targeted receptor agonists. Additionally, advancements in synthetic manufacturing techniques are reducing production hurdles, thereby enabling wider commercial availability. Highlighting this momentum, the American Chemical Society reported that in 2023, the FDA approved nine peptide and oligonucleotide therapeutics, accounting for 16% of the year's total new drug approvals.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 56.90 Billion
Market Size 2031USD 96.73 Billion
CAGR 2026-20319.25%
Fastest Growing SegmentMetabolic Disorders
Largest MarketNorth America

Despite this positive outlook, the industry confronts significant obstacles regarding drug delivery and stability. Peptides generally suffer from low oral bioavailability and are quickly cleared from the bloodstream due to enzymatic degradation, often requiring frequent invasive injections. This necessity for parenteral administration complicates patient compliance and restricts the broader application of peptide-based therapies in managing chronic conditions. Consequently, overcoming these pharmacokinetic limitations remains a pivotal challenge for the sector as it seeks to enhance the convenience and effectiveness of long-term treatment regimens.

Market Driver

The surging global incidence of metabolic and chronic conditions, particularly type 2 diabetes and obesity, acts as a primary catalyst for market expansion. This increasing disease burden has directed clinical attention toward Glucagon-like peptide-1 (GLP-1) receptor agonists, known for their efficacy in regulating appetite and insulin secretion. As a result, major pharmaceutical companies are seeing substantial revenue growth from their metabolic peptide divisions, prompting a need for scaled-up production. For instance, Novo Nordisk's 2023 Annual Report revealed that sales within its Obesity Care division rose by 154% at constant exchange rates to 41.6 billion Danish kroner in February 2024, underscoring the vital role these therapeutics play in lifestyle disease management and the commercial success derived from these targeted biological molecules.

A secondary driver is the vigorous expansion of biopharmaceutical research and development, coupled with strategic mergers and acquisitions designed to secure innovative peptide assets. Major pharmaceutical corporations are actively acquiring specialized biotech firms to gain access to next-generation dual and triple agonists, a strategy that mitigates early-stage risks and accelerates product launches. Notably, in December 2023, Roche agreed to acquire the peptide developer Carmot Therapeutics for an upfront payment of 2.7 billion US dollars, demonstrating the industry's dedication to broadening pipelines beyond traditional insulin. To support this growth, manufacturers are also heavily investing in infrastructure; in November 2023, Eli Lilly and Company pledged 2.5 billion dollars to build a new manufacturing facility in Germany, specifically to enhance its parenteral peptide supply capabilities.

Market Challenge

The primary obstacle impeding the Global Peptide Therapeutics Market is the intrinsic instability of peptide molecules combined with significant drug delivery difficulties. Peptides are prone to rapid degradation by enzymes in the gastrointestinal tract and circulation, leading to limited oral bioavailability and brief half-lives. Consequently, invasive administration methods such as subcutaneous or intravenous injections are often required to ensure the medication reaches its intended target with adequate potency. This reliance on frequent injections poses a substantial hurdle to patient adherence, especially for chronic conditions requiring long-term treatment, which in turn restricts the addressable patient base and hampers overall market penetration.

Furthermore, the complexity involved in developing stable and effective delivery systems retards the progress of new products through regulatory pathways. The challenge of formulating these molecules is reflected in approval statistics; according to the Regulatory Affairs Professionals Society, only two novel peptide therapeutics received FDA approval in 2024, comprising a mere 4% of the 50 new molecular entities authorized that year. This low approval rate relative to traditional small molecules highlights the enduring struggle developers face in resolving stability concerns, directly limiting the number of new therapies that successfully enter the commercial market.

Market Trends

The incorporation of artificial intelligence into peptide discovery is transforming the research and development landscape by addressing longstanding challenges such as optimizing membrane permeability and metabolic stability. Advanced computational platforms now facilitate the rapid screening of extensive virtual libraries, allowing researchers to pinpoint candidates with superior binding affinity and pharmacokinetic properties prior to physical synthesis. This technological evolution enables developers to shorten discovery schedules and decrease the high failure rates typical of early-stage development. Illustrating this trend, BioDuro announced a strategic partnership with Atombeat in August 2025, deploying an AI-driven platform capable of evaluating over one trillion potential peptide compounds to accelerate the identification of viable therapeutic candidates.

Simultaneously, the emergence of next-generation Peptide Drug Conjugates (PDCs) marks a significant advancement in targeted oncology, transitioning from simple receptor agonists to complex delivery systems that transport cytotoxic or radioactive agents directly to cancer cells. Compared to antibody-drug conjugates, PDCs offer advantages such as deeper tissue penetration and more rapid systemic clearance, which help minimize off-target toxicity while maintaining potency against solid tumors. This trend is highlighted by a marked increase in clinical efforts surrounding radioligand therapies and innovative linker technologies; a June 2025 report by WuXi AppTec noted that over 30 radioligand drug conjugate clinical trials were initiated in 2024, representing a threefold increase over the previous five years.

Key Market Players

  • Eli Lilly and Co.
  • Pfizer Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Co Ltd.
  • AstraZeneca Pharmaceuticals LP
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • F Hoffmann-La Roche AG
  • Novartis AG
  • Novo Nordisk A/S

Report Scope

In this report, the Global Peptide Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Therapeutics Market, By Application

  • Cancer
  • Metabolic Disorders
  • Cardiovascular Disorders
  • Respiratory Disorders
  • Gastrointestinal Disorders
  • Infectious Diseases
  • Pain
  • Dermatological Disorders
  • Neurological Disorders
  • Renal Disorders
  • Others

Peptide Therapeutics Market, By Type

  • Generic
  • Innovative

Peptide Therapeutics Market, By Type of Manufacturers

  • In-house
  • Outsourced

Peptide Therapeutics Market, By Route of Administration

  • Parenteral Route
  • Oral Route
  • Pulmonary
  • Mucosal
  • Others

Peptide Therapeutics Market, By Synthesis Technology

  • Solid Phase Peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid Technology

Peptide Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptide Therapeutics Market.

Available Customizations:

Global Peptide Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptide Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Cancer, Metabolic Disorders, Cardiovascular Disorders, Respiratory Disorders, Gastrointestinal Disorders, Infectious Diseases, Pain, Dermatological Disorders, Neurological Disorders, Renal Disorders, Others)
    • 5.2.2. By Type (Generic, Innovative)
    • 5.2.3. By Type of Manufacturers (In-house, Outsourced)
    • 5.2.4. By Route of Administration (Parenteral Route, Oral Route, Pulmonary, Mucosal, Others)
    • 5.2.5. By Synthesis Technology (Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Peptide Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Type
    • 6.2.3. By Type of Manufacturers
    • 6.2.4. By Route of Administration
    • 6.2.5. By Synthesis Technology
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Peptide Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Type of Manufacturers
        • 6.3.1.2.4. By Route of Administration
        • 6.3.1.2.5. By Synthesis Technology
    • 6.3.2. Canada Peptide Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Type of Manufacturers
        • 6.3.2.2.4. By Route of Administration
        • 6.3.2.2.5. By Synthesis Technology
    • 6.3.3. Mexico Peptide Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Type of Manufacturers
        • 6.3.3.2.4. By Route of Administration
        • 6.3.3.2.5. By Synthesis Technology

7. Europe Peptide Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Type
    • 7.2.3. By Type of Manufacturers
    • 7.2.4. By Route of Administration
    • 7.2.5. By Synthesis Technology
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Peptide Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Type of Manufacturers
        • 7.3.1.2.4. By Route of Administration
        • 7.3.1.2.5. By Synthesis Technology
    • 7.3.2. France Peptide Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Type of Manufacturers
        • 7.3.2.2.4. By Route of Administration
        • 7.3.2.2.5. By Synthesis Technology
    • 7.3.3. United Kingdom Peptide Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Type of Manufacturers
        • 7.3.3.2.4. By Route of Administration
        • 7.3.3.2.5. By Synthesis Technology
    • 7.3.4. Italy Peptide Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Type of Manufacturers
        • 7.3.4.2.4. By Route of Administration
        • 7.3.4.2.5. By Synthesis Technology
    • 7.3.5. Spain Peptide Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Type of Manufacturers
        • 7.3.5.2.4. By Route of Administration
        • 7.3.5.2.5. By Synthesis Technology

8. Asia Pacific Peptide Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Type
    • 8.2.3. By Type of Manufacturers
    • 8.2.4. By Route of Administration
    • 8.2.5. By Synthesis Technology
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Peptide Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Type of Manufacturers
        • 8.3.1.2.4. By Route of Administration
        • 8.3.1.2.5. By Synthesis Technology
    • 8.3.2. India Peptide Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Type of Manufacturers
        • 8.3.2.2.4. By Route of Administration
        • 8.3.2.2.5. By Synthesis Technology
    • 8.3.3. Japan Peptide Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Type of Manufacturers
        • 8.3.3.2.4. By Route of Administration
        • 8.3.3.2.5. By Synthesis Technology
    • 8.3.4. South Korea Peptide Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Type of Manufacturers
        • 8.3.4.2.4. By Route of Administration
        • 8.3.4.2.5. By Synthesis Technology
    • 8.3.5. Australia Peptide Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Type of Manufacturers
        • 8.3.5.2.4. By Route of Administration
        • 8.3.5.2.5. By Synthesis Technology

9. Middle East & Africa Peptide Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Type
    • 9.2.3. By Type of Manufacturers
    • 9.2.4. By Route of Administration
    • 9.2.5. By Synthesis Technology
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Peptide Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Type of Manufacturers
        • 9.3.1.2.4. By Route of Administration
        • 9.3.1.2.5. By Synthesis Technology
    • 9.3.2. UAE Peptide Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Type of Manufacturers
        • 9.3.2.2.4. By Route of Administration
        • 9.3.2.2.5. By Synthesis Technology
    • 9.3.3. South Africa Peptide Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Type of Manufacturers
        • 9.3.3.2.4. By Route of Administration
        • 9.3.3.2.5. By Synthesis Technology

10. South America Peptide Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Type
    • 10.2.3. By Type of Manufacturers
    • 10.2.4. By Route of Administration
    • 10.2.5. By Synthesis Technology
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Peptide Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Type of Manufacturers
        • 10.3.1.2.4. By Route of Administration
        • 10.3.1.2.5. By Synthesis Technology
    • 10.3.2. Colombia Peptide Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Type of Manufacturers
        • 10.3.2.2.4. By Route of Administration
        • 10.3.2.2.5. By Synthesis Technology
    • 10.3.3. Argentina Peptide Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Type of Manufacturers
        • 10.3.3.2.4. By Route of Administration
        • 10.3.3.2.5. By Synthesis Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Peptide Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Eli Lilly and Co.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Amgen Inc.
  • 15.4. Takeda Pharmaceutical Co Ltd.
  • 15.5. AstraZeneca Pharmaceuticals LP
  • 15.6. Teva Pharmaceutical Industries Ltd.
  • 15.7. Sanofi S.A.
  • 15.8. F Hoffmann-La Roche AG
  • 15.9. Novartis AG
  • 15.10. Novo Nordisk A/S

16. Strategic Recommendations

17. About Us & Disclaimer